Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Voyager Therapeutics (VYGR) over the last 10 years, with Q3 2025 value amounting to $400000.0.

  • Voyager Therapeutics' Other Non Operating Income rose 10000.0% to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 64863.64%. This contributed to the annual value of $622000.0 for FY2024, which is 2063333.33% up from last year.
  • As of Q3 2025, Voyager Therapeutics' Other Non Operating Income stood at $400000.0, which was up 10000.0% from $427000.0 recorded in Q2 2025.
  • Voyager Therapeutics' Other Non Operating Income's 5-year high stood at $3.9 million during Q1 2021, with a 5-year trough of -$1.6 million in Q2 2021.
  • Its 5-year average for Other Non Operating Income is $530071.4, with a median of $300000.0 in 2024.
  • Per our database at Business Quant, Voyager Therapeutics' Other Non Operating Income plummeted by 334130.43% in 2021 and then skyrocketed by 245446.43% in 2022.
  • Voyager Therapeutics' Other Non Operating Income (Quarter) stood at $650000.0 in 2021, then plummeted by 103.54% to -$23000.0 in 2022, then soared by 113.04% to $3000.0 in 2023, then surged by 13300.0% to $402000.0 in 2024, then decreased by 0.5% to $400000.0 in 2025.
  • Its last three reported values are $400000.0 in Q3 2025, $427000.0 for Q2 2025, and $418000.0 during Q1 2025.